bioAffinity Tech Stock Price, News & Analysis

bioAffinity Technologies (NASDAQ: BIAF), a biotechnology company focused on early-stage cancer detection, has secured approximately $1.2 million in gross proceeds through a private placement and warrant inducement transaction. The company is selling 990 shares of Series B Convertible Preferred Stock at $1,000 per share, convertible into approximately 4.3 million common shares at $0.23 per share.

The deal includes warrants to purchase about 6.7 million common shares at $0.352 per share. Additionally, an existing investor agreed to exercise warrants for 1.1 million shares at reduced prices, providing $253,000 in immediate proceeds. The transaction, managed by WallachBeth Capital, is expected to close around August 14, 2025. Proceeds will support working capital and general corporate purposes.

bioAffinity Technologies (NASDAQ: BIAF) has announced a private placement and warrant inducement transaction expected to generate approximately $1.2 million in gross proceeds. The company is selling 990 shares of Series B Convertible Preferred Stock at $1,000 per share, convertible into approximately 4.3 million common shares at $0.23 per share.

The transaction includes warrants to purchase about 6.7 million common shares at $0.352 per share. Additionally, an existing investor will exercise warrants for 1.1 million shares at reduced prices, generating $253,000 in proceeds. The closing is expected around August 14, 2025, with proceeds intended for working capital and general corporate purposes.

bioAffinity Technologies (NASDAQ: BIAF) reported significant growth in sales of its CyPath® Lung cancer diagnostic test. July test volume showed a 72% increase over the previous monthly average for H1 2025, marking consecutive record-breaking months in June and July.

The company reaffirmed its forecast of 3X year-over-year revenue growth for CyPath® Lung. The growth is attributed to increasing physician adoption and successful case studies showing the test's ability to detect Stage 1A lung cancer in cases where standard imaging and other tests indicated benign conditions.

bioAffinity is expanding beyond its successful Texas pilot program into the Mid-Atlantic region and Veterans Administration healthcare system. The company's Texas program, reaching approximately 6% of U.S. pulmonologists, has validated their marketing approach.

bioAffinity Technologies (NASDAQ: BIAF) has reported a significant case study demonstrating the effectiveness of its CyPath® Lung diagnostic test in detecting early-stage lung cancer. The test successfully identified Stage 1A pulmonary mucinous adenocarcinoma in a 62-year-old high-risk patient when other diagnostic methods showed low cancer probability.

The patient's traditional diagnostic results, including PET scan and blood-based risk test, indicated only an 11% malignancy risk. However, CyPath® Lung's test result of 0.56 classified the case as "likely malignancy," leading to successful surgical intervention through wedge resection in June 2025.

This case highlights CyPath® Lung's capability to detect rare cancer types that are often missed by standard imaging, potentially enabling life-saving early interventions.

bioAffinity Technologies (NASDAQ: BIAF) has released a case study demonstrating the effectiveness of their CyPath® Lung diagnostic test in detecting early-stage lung cancer. The test successfully identified a Stage 1A neuroendocrine tumor in an 80-year-old former smoker after other diagnostic methods, including PET scan and bronchoscopies, failed to detect malignancy.

The CyPath® Lung test returned a high score of 0.72, indicating cancer likelihood, which led to a robotic wedge resection that confirmed the presence of the tumor. This case highlights the test's potential as a valuable complement to traditional diagnostic tools, particularly for difficult-to-detect cancers in patients with indeterminate pulmonary nodules.

bioAffinity Technologies (NASDAQ: BIAF) has secured a new patent in Canada for its CyPath® Lung cancer diagnostic technology. The patent (No. 3,136,245) protects the company's method of detecting lung disease through flow cytometry analysis of sputum using defined antibodies and porphyrin TCPP.

CyPath® Lung, the company's commercially available test, has demonstrated impressive clinical results with 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small lung nodules under 20 millimeters. The Canadian market represents a significant opportunity, as lung cancer is the leading cause of cancer death in Canada, with 31,000 diagnoses and 20,700 deaths reported in 2024.

bioAffinity Technologies (NASDAQ: BIAF) has received patent allowance from China's National Intellectual Property Administration for its lung cancer diagnostic method using flow cytometry. The patent, titled "System and Method for Determining Lung Health," protects the company's technology using specific antibodies and porphyrin TCPP to detect lung cancer cells in sputum.

China represents a significant market opportunity with over 300 million smokers and an estimated 1.06 million new lung cancer cases in 2022. The company's CyPath® Lung test has demonstrated impressive clinical results, including 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small lung nodules.

bioAffinity Technologies (NASDAQ: BIAF) released a compelling case study demonstrating the effectiveness of their CyPath® Lung test in detecting early-stage lung cancer. The test successfully identified Stage 1A adenocarcinoma in a 70-year-old female patient when other diagnostic methods were inconclusive.

The case involved a high-risk patient with a 50+ pack-year smoking history and COPD. While PET imaging and risk models suggested low malignancy probability (0.2%), CyPath® Lung's positive result (0.83) led to surgical intervention, confirming early-stage cancer. The test is Medicare-reimbursed and available through Federal Supply Schedule, with potential cost savings of $2,733 per Medicare patient and $6,460 per private insurance patient.

bioAffinity Technologies (NASDAQ: BIAF) is presenting breakthrough cancer research at the 2025 RNA Therapeutics Conference, highlighting their patented therapeutic approach using small interfering RNAs (siRNAs) to target CD320 and LRP2 cell surface receptors. The research demonstrates selective cancer cell elimination while preserving normal cells.

The company's technology, protected by U.S. Patent No. 12,305,171 and a recently granted Chinese patent, shows promise across multiple cancer types including lung, breast, prostate, brain, and skin cancers. Research is currently focused on developing a topical treatment for skin malignancies. The presentation titled "Silencing CD320 and LRP2 by siRNAs selectively kills cancer cells: mechanistic enigmas" will be delivered by Dr. David Elzi, VP of Product Development.